DAYVIGO® From Eisai

DAYVIGO® (lemborexant) is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. 


At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.

“The materials for DAYVIGO (lemborexant) CIV contained in this virtual exhibit are approved for use only in the United States. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to your local prescribing information and consult directly the local affiliate of the relevant company to address any questions.”

Educational Resources for Providers
Explore the safety profile, special safety studies, dosing and administration, and additional resources for DAYVIGO®.

Download HCP Brochure

Support for Patients
This brochure outlines available services to help patients access the treatment they need. 

Download Patient Brochure


 

Brought to you by Eisai, Inc. 

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.

“The materials for DAYVIGO (lemborexant) CIV contained in this virtual exhibit are approved for use only in the United States. Prescribing information may vary depending on local approval in each country. Therefore, before prescribing any product, always refer to your local prescribing information and consult directly the local affiliate of the relevant company to address any questions.”

 


 

The content and information contained on this site is being provided as a convenience and for informational purposes only. The posting of sponsored content on this site should not be considered an endorsement or recommendation of the sponsor's products, services, policies, or procedures by the American Association of Nurse Practitioners (AANP). The information and opinions expressed on this page are those of the paid sponsors and do not necessarily reflect the view of the AANP. AANP is not responsible for the content of third-party websites linked from this page; moreover, any links on this page to third-party websites where goods or services are advertised are not endorsements or recommendations by AANP of the third-party sites, goods, or services.

Loading